These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. New Treatments and Insights in Multiple Myeloma. Faiman B; Noonan K ONS Connect; 2016 Jun; 31(6):4 p following 31. PubMed ID: 27430103 [No Abstract] [Full Text] [Related]
23. [Multiple melanoma-progress in understanding of molecular mechanism and improvement in treatment outcome with introduction of new drugs for multiple myeloma]. Hanamura I; Iida S Gan To Kagaku Ryoho; 2010 May; 37(5):816-21. PubMed ID: 20524255 [No Abstract] [Full Text] [Related]
24. The use of topoisomerase I inhibitors in multiple myeloma. Kraut EH; Ju R; Muller M Semin Hematol; 1998 Jul; 35(3 Suppl 4):32-8. PubMed ID: 9779880 [TBL] [Abstract][Full Text] [Related]
25. Searching for truth--from biblical to modern times. Antman KH J Clin Oncol; 1986 Oct; 4(10):1441-2. PubMed ID: 3760918 [No Abstract] [Full Text] [Related]
26. [Therapeutic experiences in multiple myeloma]. Sonntag R; Favre E; Martz G Schweiz Med Wochenschr; 1972 Nov; 102(44):1588-9. PubMed ID: 4566555 [No Abstract] [Full Text] [Related]
27. Clinical management of myeloma--state of the art. Harousseau JL Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182 [TBL] [Abstract][Full Text] [Related]
28. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002. Dalton WS Clin Cancer Res; 2002 Dec; 8(12):3643-5. PubMed ID: 12473572 [No Abstract] [Full Text] [Related]
35. Lenalidomide and its role in the management of multiple myeloma. Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796 [TBL] [Abstract][Full Text] [Related]
36. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Bross PF; Kane R; Farrell AT; Abraham S; Benson K; Brower ME; Bradley S; Gobburu JV; Goheer A; Lee SL; Leighton J; Liang CY; Lostritto RT; McGuinn WD; Morse DE; Rahman A; Rosario LA; Verbois SL; Williams G; Wang YC; Pazdur R Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3954-64. PubMed ID: 15217925 [No Abstract] [Full Text] [Related]
37. Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation. Richardson P Oncology (Williston Park); 2006 May; 20(6):633-8. PubMed ID: 16773847 [No Abstract] [Full Text] [Related]
38. Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value. Gaultney JG; Redekop WK; Sonneveld P; Uyl-de Groot CA Expert Rev Anticancer Ther; 2012 Jun; 12(6):839-54. PubMed ID: 22716498 [TBL] [Abstract][Full Text] [Related]
39. Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice. SanMiguel J; Facon T; Cavo M Clin Adv Hematol Oncol; 2008 Apr; 6(4):s4-s10. PubMed ID: 18567204 [No Abstract] [Full Text] [Related]